Boston Scientific Announces Global Restructuring amid Investor Activity

Boston Scientific disclosed a worldwide restructuring plan that includes a reduction of staff to streamline operations. The move is part of a broader shift in the medical‑device sector toward automation, artificial intelligence and advanced technology, according to former Costa Rican vice‑minister of foreign trade John Fonseca. He noted that such changes affect how foreign direct investment is evaluated, emphasizing the importance of job quality, knowledge transfer and integration with local economies.

In parallel, institutional investors are adjusting their positions in the company. Janus Henderson Group PLC increased its stake by purchasing nearly 3.9 million shares, bringing its ownership to 1.11 percent of Boston Scientific. Meanwhile, TD Cowen cut its price target for the stock to $56.00 from $61.00, reflecting a more cautious outlook despite a current "buy" rating.

Analysts across the sector have also revised their ratings and targets, citing the recent earnings report and the company's strategic realignment. These developments highlight both the financial market's response to Boston Scientific's operational changes and the broader industry trend toward technology‑driven productivity.